These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29187466)

  • 1. A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
    Mokbel K; Wazir U; El Hage Chehade H; Manson A; Choy C; Moye V; Mokbel K
    Anticancer Res; 2017 Dec; 37(12):6863-6869. PubMed ID: 29187466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER
    Mokbel K; Wazir U; Wazir A; Kasem A; Mokbel K
    Anticancer Res; 2018 Aug; 38(8):4747-4752. PubMed ID: 30061244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
    Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
    Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
    Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
    Ettl J; Anders SI; Hapfelmeier A; Paepke S; Noske A; Weichert W; Klein E; Kiechle M
    Arch Gynecol Obstet; 2020 Dec; 302(6):1461-1467. PubMed ID: 32902674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer.
    Klein E; Kiechle M; Josipovic A; Anders SI; Noske A; Mogler C; Hapfelmeier A; Ettl J
    Breast Cancer Res Treat; 2024 Aug; 207(1):119-127. PubMed ID: 38722442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
    Dubsky P; Filipits M; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Kronenwett R; Brase JC; Gnant M;
    Ann Oncol; 2013 Mar; 24(3):640-7. PubMed ID: 23035151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
    Blank PR; Filipits M; Dubsky P; Gutzwiller F; Lux MP; Brase JC; Weber KE; Rudas M; Greil R; Loibl S; Szucs TD; Kronenwett R; Schwenkglenks M; Gnant M
    Pharmacoeconomics; 2015 Feb; 33(2):179-90. PubMed ID: 25404424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
    Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
    Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
    PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
    Penault-Llorca F; Kwiatkowski F; Arnaud A; Levy C; Leheurteur M; Uwer L; Derbel O; Le Rol A; Jacquin JP; Jouannaud C; Quenel-Tueux N; Girre V; Foa C; Guardiola E; Lortholary A; Catala S; Guiu S; Valent A; Boinon D; Lemonnier J; Delaloge S
    Breast; 2020 Feb; 49():132-140. PubMed ID: 31790959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
    Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
    Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
    Constantinidou A; Marcou Y; Toss MS; Simmons T; Bernhisel R; Hughes E; Probst B; Meek S; Kakouri E; Georgiou G; Zouvani I; Savvidou G; Kuhl V; Doedt J; Wagner S; Gutin A; Slavin TP; Lanchbury JS; Kronenwett R; Ellis IO; Rakha EA
    Clin Cancer Res; 2022 Oct; 28(20):4435-4443. PubMed ID: 36043530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
    Penault-Llorca F; Dalenc F; Chabaud S; Cottu P; Allouache D; Cameron D; Grenier J; Venat Bouvet L; Jegannathen A; Campone M; Debled M; Hardy-Bessard AC; Giacchetti S; Barthelemy P; Kaluzinski L; Mailliez A; Mouret-Reynier MA; Legouffe E; Cayre A; Martinez M; Delbaldo C; Mollon-Grange D; Macaskill EJ; Sephton M; Stefani L; Belgadi B; Winter M; Orfeuvre H; Lacroix-Triki M; Bonnefoi H; Bliss J; Canon JL; Lemonnier J; Andre F; Bachelot T
    ESMO Open; 2024 May; 9(5):103443. PubMed ID: 38692082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EndoPredict
    Almstedt K; Mendoza S; Otto M; Battista MJ; Steetskamp J; Heimes AS; Krajnak S; Poplawski A; Gerhold-Ay A; Hasenburg A; Denkert C; Schmidt M
    Breast Cancer Res Treat; 2020 Jul; 182(1):137-146. PubMed ID: 32436145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions.
    Müller BM; Keil E; Lehmann A; Winzer KJ; Richter-Ehrenstein C; Prinzler J; Bangemann N; Reles A; Stadie S; Schoenegg W; Eucker J; Schmidt M; Lippek F; Jöhrens K; Pahl S; Sinn BV; Budczies J; Dietel M; Denkert C
    PLoS One; 2013; 8(6):e68252. PubMed ID: 23826382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
    Fallowfield L; Matthews L; May S; Jenkins V; Bloomfield D
    Psychooncology; 2018 Apr; 27(4):1264-1269. PubMed ID: 29448311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
    Jank P; Lindner JL; Lehmann A; Pfitzner BM; Blohmer JU; Horst D; Kronenwett R; Denkert C; Schmitt WD
    Breast Cancer Res Treat; 2022 Jan; 191(2):327-333. PubMed ID: 34783927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
    Noske A; Anders SI; Ettl J; Hapfelmeier A; Steiger K; Specht K; Weichert W; Kiechle M; Klein E
    Breast; 2020 Feb; 49():101-107. PubMed ID: 31786414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
    Peláez-García A; Yébenes L; Berjón A; Angulo A; Zamora P; Sánchez-Méndez JI; Espinosa E; Redondo A; Heredia-Soto V; Mendiola M; Feliú J; Hardisson D
    PLoS One; 2017; 12(9):e0183452. PubMed ID: 28886093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.